Acid Sphingomyelinase Deficiency (ASMD) Market Dynamics: Impact of Rare Disease
The global acid sphingomyelinase deficiency (ASMD) market consists of drugs that are used for the treatment of ASMD. ASMD is a rare genetic disorder caused due to the deficiency of the enzyme acid sphingomyelinase, which breaks down sphingomyelin. People with ASMD may experience liver disease, lung disease, and other symptoms. The current treatment options for ASMD include enzyme replacement therapy and hematopoietic stem cell transplantation.
The acid sphingomyelinase deficiency (ASMD) market is estimated to be valued at USD 134.6 Mn in 2024 and is expected to reach USD 300 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.
The growing demand for effective treatment options is expected to drive the Acid Sphingomyelinase Deficiency (ASMD) Market during the forecast period. Due to the rare occurrence of ASMD, only a limited patient pool requires treatment. However, the availability of diagnostic techniques and increasing disease awareness are supporting the identification of new patients.
Get More Insights On- Acid Sphingomyelinase Deficiency (ASMD) Market
Get This Report in Japanese Language: 酸性スフィンゴミエリナーゼ欠損症市場
Get This Report in Korean Language: 산성 스핑고미엘린 분해효소 결핍증 시장
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian